Showing results (111-120 of 197) with videos related to
Sort By:
Pageof 20
Journal of the American Academy of Dermatology|October 16, 2007
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialAlan Menter, Stephen K Tyring, Kenneth Gordon, et al.Dermatology and Therapy|November 26, 2024
Brodalumab: Six-Year US Pharmacovigilance ReportMark G Lebwohl, John Y Koo, April W Armstrong, et al.Dermatology and Therapy|April 4, 2026
Envudeucitinib, a Potent, Next-Generation, Allosteric Inhibitor of TYK2: A Narrative ReviewApril W Armstrong, James G Krueger, Bruce E Strober, et al.Journal of the American Academy of Dermatology|March 4, 2008
National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screeningAlexa B Kimball, Dafna Gladman, Joel M Gelfand, et al.Journal of the American Academy of Dermatology|February 21, 2006
Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasisKim A Papp, Bruce Miller, Kenneth B Gordon, et al.The Journal of Dermatological Treatment|February 10, 2006
Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapyKenneth B Gordon, Alice B Gottlieb, Craig L Leonardi, et al.Dermatology (Basel, Switzerland)|December 15, 2010
Clinical and cytological effects of pimecrolimus cream 1% after resolution of active atopic dermatitis lesions by topical corticosteroids: a randomized controlled trialChristine Bangert, Bruce E Strober, Michael Cork, et al.Journal of Drugs in Dermatology : JDD|December 31, 2004
Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasisAlice B Gottlieb, Kenneth B Gordon, Mark G Lebwohl, et al.Seminars in Cutaneous Medicine and Surgery|July 18, 2018
Highlights of Skin Disease Education Foundations 42nd Annual Hawaii Dermatology SeminarHilary E Baldwin, Linda F Stein Gold, Kenneth B Gordon, et al.Journal of the American Academy of Dermatology|September 23, 2014
A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasisKenneth B Gordon, Craig L Leonardi, Mark Lebwohl, et al.Pageof 20